Table 1.
Comparison for baseline characteristics of participants.
| Parameters | Cerebrolysin (n = 59) | Placebo (n = 51) | p-Value |
|---|---|---|---|
| Sex (male:female) | 34:25 | 32:19 | 0.585 |
| Age (mean ± SD, years) | 68.6 ± 10.8 | 66.1 ± 12.8 | 0.246 |
| Stroke side (Rt:Lt) | 21:38 | 26:25 | 0.104 |
| Baseline stroke severity (mean ± SD) | |||
| NIHSS | 9.0 ± 3.9 | 9.0 ± 4.0 | 0.882 |
| MMSE | 19.6 ± 9.0 | 18.7 ± 10.1 | 0.618 |
| FMA-T | 26.2 ± 13.6 | 21.6 ± 13.7 | 0.085 |
| FMA-UL | 12.8 ± 9.9 | 10.6 ± 8.4 | 0.220 |
| FMA-LL | 13.4 ± 7.4 | 11.0 ± 7.4 | 0.097 |
| Lesion volume (cm3) | 43.9 ± 66.7 | 69.9 ± 90.5 | 0.117 |
| MEP response (n (%)) | 13 (22.0%) | 10 (19.6%) | 0.817 |
NIHSS, National Institutes of Health Stroke Scale; MMSE, Mini-Mental State Examination; FMA-T, total Fugl–Meyer assessment; FMA-UL, upper limb of Fugl–Meyer assessment; FMA-LL, lower limb of Fugl–Meyer assessment; MEP, motor evoked potential.